<DOC>
	<DOCNO>NCT02342587</DOCNO>
	<brief_summary>Although anti-HER2 ( human epidermal growth factor receptor 2 ) therapy currently approve breast , gastric , gastroesophageal cancer overexpressing HER2 protein amplify HER2 gene , HER2 aberration ( gene amplification , gene mutation , protein overexpression ) report diverse malignancy . Indeed , 1-37 % tumor follow type harbor HER2 aberration : bladder , cervix , colon , endometrium , germ cell , glioblastoma , head neck , liver , lung , ovarian , pancreas , salivary duct . Lapatinib orally active , reversible , small molecule TKI potently inhibit ErbB1 ErbB2 tyrosine kinase activity . Data suggest dual ErbB1 ErbB2 inhibitor may provide improve therapeutic benefit compare inhibitor target one receptor . Therefore , phase 2 study design evaluated activity lapatinib patient HER2-positive refractory cancer .</brief_summary>
	<brief_title>Safety Clinical Activity Lapatinib Patients With HER2-positive Refractory Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Age &gt; 19 Written inform consent ECOG 02 , Histologically confirm HER2positive Refractory solid tumor ( IHC 3+ alone , IHC 2+ FISH amplification ) and/or specific sensitivity Lapatinib Avatar scan progress follow standard therapy respond standard therapy standard therapy . The presence measurable disease define Response ( Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 ) Adequate organ function Uncontrolled symptomatic brain metastasis , Uncontrolled active infection Uncontrolled systemic illness ( DM , CHF , unstable angina , hypertension arrhythmia ) Prolonged QT interval ECG ( QTc &gt; 450 msec ) Pregnant , lactate woman Prior treatment lapatinib , Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel , person unable swallow oral medication Prior history malignancy within 5 year study entry except adequately treat basal cell squamous cell skin cancer situ cervical cancer , welltreated thyroid cancer</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lapatinib</keyword>
</DOC>